Repligen (RGEN) Q1 2025: Non-COVID Organic Growth Hits 14% as Order Funnel Expands 30%

April 29, 2025 | By EarningsIQ Research

Repligen’s Q1 saw robust non-COVID organic growth and a 30% jump in high-probability pipeline opportunities, driven by broad-based demand across bioprocessing franchises and geographies. Order momentum and a diversified customer base underpin management’s confidence in above-market growth for 2025, even as macro and tariff headwinds persist. Strategic M&A integration, product innovation, and resilient execution position Repligen for continued share gains in a dynamic bioprocessing market.

Summary

• Order Momentum Surges: High teens order growth and a 30% increase in the opportunity funnel signal expanding demand visibility.
• Tariff Impact Contained: Management expects minimal EPS risk from tariffs, leveraging US manufacturing and pricing actions.
• Strategic Execution Drives Confidence: M&A integration, product launches, and operational discipline support sustained outperformance.

Performance Analysis

Repligen delivered 14% organic non-COVID revenue growth in Q1, with reported revenue up 10% and organic growth at 11%. The quarter was marked by broad-based strength: proteins led all franchises, chromatography and analytics posted double-digit gains, and consumables set a new record. Capital equipment lagged as expected due to timing, but backlog supports a rebound in the second half. Geographically, North America and Europe each contributed 13% growth and together comprised 85% of total revenue, while China’s continued decline left it at just 2% of the business.

Gross margin expanded by nearly 450 basis points to 53.7%, propelled by volume leverage, favorable product mix, and productivity gains. Operating income margin rose 490 basis points to 13.8%, with operating expense growth held well below revenue growth. Adjusted net income rose 29% year-over-year, and cash generation remained solid despite acquisition outflows. Orders grew high teens year-over-year across all franchises, and the high-probability opportunity funnel expanded 30%, reflecting robust underlying demand.

• Consumables Drive Record Results: Consumable revenues (excluding proteins) grew over 20% year-over-year, with design wins in late-phase and commercial drugs providing a tailwind.
• CDMO Order Strength: Contract development and manufacturing organization (CDMO) orders rose more than 40% year-over-year, though revenue dipped after two strong quarters.
• Protein and Chromatography Outperformance: Proteins exceeded expectations, and chromatography order intake hit a three-year high, driven by large-scale column demand and expanding pharma adoption.

Management’s disciplined cost control, combined with broad-based order growth and a diversified customer mix, set a strong foundation for 2025 guidance and continued margin gains.

Executive Commentary

Strategic Positioning

1. Tariff Resilience and Global Manufacturing Flexibility

Repligen has proactively structured its manufacturing footprint to shield against tariff volatility, with over 90% of US revenue either produced domestically or tariff-exempt. Only about 10% of cost of goods sold is exposed to imported raw materials, and management estimates low single-digit revenue exposure to tariffs. Surcharges and selective pricing actions are expected to offset most cost impact, resulting in minimal EPS risk. The company is also prepared to shift production across its global network if retaliatory tariffs emerge in Europe or Asia.

2. Diversified Customer Exposure and End-Market Balance

Repligen’s customer base is notably diversified, with its largest monoclonal antibody customer at just 6% of revenue and its largest new modality customer below 3%. The commercial-to-clinical revenue mix remains stable at 35% commercial, but underlying growth in commercial programs is accelerating as design wins move from clinical to commercial phases. This broad exposure insulates the business from idiosyncratic risk and positions Repligen to capture secular bioprocessing growth.

3. M&A Integration and Innovation Pipeline

The acquisition of 908 Devices’ bioprocessing PAT (process analytical technology) portfolio enhances Repligen’s digitization strategy and complements its downstream capabilities. Integration is on track, with commercial and R&D teams aligned to drive cross-selling and accelerate new product launches. The MetaNova-based MixOne single-use mixer, launched in Q1, exemplifies Repligen’s ability to combine acquired technologies into differentiated solutions, with initial orders expected in the second half of 2025.

4. Operational Discipline and Margin Expansion

Margin improvement was driven by productivity initiatives, volume leverage, and favorable product mix, with management signaling continued focus on cost control and operational efficiency. OPEX growth is running at less than half the rate of revenue growth, and CapEx is being reduced 20-25% year-over-year, returning to pre-COVID levels. This discipline provides dry powder for future M&A while supporting organic growth investments.

Key Considerations

Repligen’s Q1 results underscore its ability to deliver above-market growth while navigating macro and industry-specific headwinds. The company’s strategic initiatives and operational rigor provide multiple levers to sustain momentum.

Key Considerations:

• Order Funnel Expansion: A 30% year-over-year increase in high-probability pipeline opportunities signals robust demand visibility beyond near-term backlog.
• CDMO and Pharma Tailwinds: Strong order growth from contract manufacturers and large pharma customers reflects broad adoption of Repligen’s portfolio, including Opus columns and ATF consumables.
• Small Biotech Weakness: Small biotech sales declined high single digits and now represent less than 10% of revenue, mirroring industry-wide funding challenges.
• Asia Strategy Reset: China exposure is minimal, but Repligen is investing in new leadership and strategies to capture future growth in China, South Korea, and Japan.
• Innovation Pipeline Execution: Continued focus on integrating M&A, accelerating product launches, and leveraging R&D synergies will be critical to maintaining differentiation.

Risks

Tariff escalation remains a watchpoint, particularly if retaliatory measures emerge in Europe or Asia, though current exposure is limited. Small biotech funding weakness could weigh on ecosystem health, and any delay in commercial adoption or regulatory disruption in new modalities poses incremental risk. Currency volatility and macro uncertainty are ongoing variables, with management providing sensitivity frameworks but not incorporating these into guidance.

Forward Outlook

For Q2 2025, Repligen expects:

• Sequential revenue growth, with organic non-COVID growth accelerating from Q1
• Continued order strength across franchises, supporting a stronger second half

For full-year 2025, management maintained or raised guidance:

• Organic non-COVID revenue growth of 11.5% to 15.5%
• Reported revenue guidance now $695 million to $720 million, reflecting 908 Devices acquisition
• Gross margin guidance increased to 52% to 53%, up 100 basis points from prior
• Adjusted EPS of $1.63 to $1.72, a slight decrease due to acquisition dilution

Management highlighted several factors that will influence outlook:

• Tariff and FX impacts are excluded from guidance, but sensitivity analysis provided
• Order and funnel strength, product launches, and operational discipline underpin confidence in above-market growth

Takeaways

Repligen’s Q1 results demonstrate broad-based demand, operational leverage, and strategic discipline, supporting its goal of sustained above-market growth in a volatile environment.

• Order Book and Funnel Strength: High teens order growth and a 30% larger pipeline provide strong visibility into future quarters, reducing reliance on restocking or one-off demand.
• Margin and Cost Control: Gross margin expansion and OPEX restraint validate the company’s operational execution and ability to offset inflationary and macro pressures.
• Innovation and M&A Integration: The ability to rapidly launch new products and integrate acquisitions like 908 Devices will be critical to sustaining differentiation and growth as the bioprocessing market evolves.

Conclusion

Repligen’s Q1 2025 performance highlights its ability to deliver consistent, above-market growth through diversified demand, operational rigor, and strategic execution. Investors should watch for continued order momentum, successful integration of new technologies, and any shifts in tariff or macro conditions that could alter the growth trajectory.

Industry Read-Through

Repligen’s results signal a resilient bioprocessing demand environment, with secular growth in biopharma manufacturing and strong adoption of single-use and analytical technologies. The company’s experience with minimal tariff impact, rapid M&A integration, and a diversified customer base provides a template for peers navigating similar macro and regulatory dynamics. Weakness in small biotech funding remains a sector-wide concern, but robust order pipelines from CDMOs and large pharma suggest continued investment in capacity and innovation. Tariff and supply chain strategies employed by Repligen may become increasingly relevant for other life sciences suppliers as global trade tensions persist.

RGEN Health Care Bioprocessing Biotech Tools Tariffs Order Funnel M&A Consumables